Skip to Content

Pfizer wants to give you a booster shot—but experts say it’s too soon

Many experts say it’s too soon for a booster when the vaccines work, and much of the world still hasn't had its first shot yet.

Pfizer vaccine in California
Mario Tama/Getty Images

Is it time to start thinking about booster shots? Pfizer seems to think so. In a private meeting with top US scientists and regulators on July 12, the firm’s representatives argued that the US should move to authorize a third shot. Last week, Pfizer and its German partner BioNTech announced that they had observed waning immunity in people who had been vaccinated and that they planned to seek emergency-use authorization for a booster dose in August. A third shot “may be beneficial to maintain the highest levels of protection,” they noted. 

Don’t expect to get that shot soon. After last week’s Pfizer announcement, the Centers for Disease Control and Prevention and the FDA issued a rare joint statement emphasizing that fully vaccinated Americans do not need a booster shot at this time. Soon after Monday’s meeting, the Department of Health and Human Services echoed that sentiment. “It was an interesting meeting. They shared their data. There wasn’t anything resembling a decision,” Anthony Fauci, President Biden’s chief medical adviser for the pandemic, told the New York Times on Monday evening.

Data from lab studies and real-world infections indicate that “the dam is holding” without boosters, says John Wherry, an immunologist at the University of Pennsylvania: “Severe infections, hospitalizations and deaths are being observed almost entirely in unvaccinated populations, even for the delta variant.” And when infections do occur in people who have been vaccinated, the symptoms tend to be mild. “This is not a vaccine failure—this is a vaccine success,” he says. 

In last week’s statement, Pfizer and BioNTech said real-world data from the Ministry of Health in Israel show that although the vaccine still provides good protection against serious illness, protection against symptomatic infection has declined in the six months after vaccination. They said that those findings were consistent with data from their own phase 3 study and noted that a third dose would be needed within six to 12 months after full vaccination. Data from the companies’ booster study suggests that a third dose boosts levels of neutralizing antibodies by a factor of five to 10. The companies are also working on a booster aimed at the delta variant.  

According to the World Health Organization (WHO), at least four countries have announced booster programs, including Israel, which has been battling a delta outbreak. The country began administering third shots on Monday to people with weakened immune systems, including cancer patients and organ transplant recipients.

About half a dozen other countries are considering the idea. If those countries also begin offering booster shots, “this will require an additional 800 million doses of vaccine,” said WHO chief scientist Soumya Swaminathan at a press briefing on Monday. 

Those doses should be going to countries that have had little access to the vaccines, said WHO director-general Tedros Adhanom Ghebreyesus. He condemned rich and middle-income countries for contemplating third doses when frontline workers and older adults in poor countries haven’t yet received their first dose. Some countries have yet to launch mass vaccination campaigns. “Currently, data shows us that vaccination offers long-lasting immunity against serious and deadly covid-19,” he said. “The priority now must be to vaccinate those who have received no doses and protection.” 

Craig Spencer, director of global health in emergency medicine at NewYork-Presbyterian/Columbia University Medical Center, put it more bluntly. “No matter what pharmaceutical companies tell you, you don’t need a Covid-19 booster more urgently than all the healthcare workers around the world who haven’t yet had access to a vaccine,” he tweeted. 

That’s not to say that we won’t need boosters eventually. “It may well be that you need boosters after a year or two years,” WHO’s Swaminathan said. Wherry notes that it’s good to be prepared. But he has not seen any data to convince him that boosters are warranted now. “The emerging data says immunity is holding strong,” he says. 

Deep Dive


What’s next for AI regulation in 2024? 

The coming year is going to see the first sweeping AI laws enter into force, with global efforts to hold tech companies accountable. 

Three technology trends shaping 2024’s elections

The biggest story of this year will be elections in the US and all around the globe

Four lessons from 2023 that tell us where AI regulation is going

What we should expect in the coming 12 months in AI policy

The FTC’s unprecedented move against data brokers, explained

It could signal more aggressive action from policy makers to curb the corrosive effects that data brokers have on personal privacy.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.